PT - JOURNAL ARTICLE AU - YUMIKO KOI AU - CHINAMI KOGA AU - SAYURI AKIYOSHI AU - TAKANOBU MASUDA AU - HIDEKI IJICHI AU - YOSHIAKI NAKAMURA AU - MAYUMI ISHIDA AU - SHINJI OHNO AU - ERIKO TOKUNAGA TI - Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer DP - 2018 Mar 01 TA - Anticancer Research PG - 1579--1584 VI - 38 IP - 3 4099 - http://ar.iiarjournals.org/content/38/3/1579.short 4100 - http://ar.iiarjournals.org/content/38/3/1579.full SO - Anticancer Res2018 Mar 01; 38 AB - Background: Previous studies have suggested that the presence of visceral metastasis is a parameter useful in predicting the treatment efficacy of fulvestrant in patients with advanced breast cancer. Patients and Methods: We retrospectively examined the association between treatment efficacy and presence of visceral metastasis in 75 patients with hormone receptor-positive recurrent breast cancer who were treated with fulvestrant or no more than five lines of other endocrine monotherapy after recurrence. Results: Nineteen patients received fulvestrant, 10 of whom had visceral metastasis. The median time to progression was 4 months for the overall study population; it was significantly longer for patients with non-visceral metastasis (5.4 months; 95% confidence interval=3.7-11.2 months) than for those with visceral metastasis (3.3 months; 95% confidence interval, 0.4-5.3 months; p=0.01). No differences in time to progression were found between the groups of patients with visceral metastasis and non-visceral metastasis who underwent other endocrine therapies. Conclusion: Fulvestrant is more effective for patients with non-visceral metastasis of recurrent breast cancer with than for those with visceral metastasis.